Minoryx Phase 2/3 ‘ADVANCE’ study results to be presented at the 2021 American Neurological Association (AAN) Annual Meeting

Minoryx Phase 2/3 ‘ADVANCE’ study…

Minoryx Therapeutics in the news

Minoryx Therapeutics in the news

Minoryx presents topline results from Phase 2/3 “ADVANCE” study demonstrating significant clinical benefit of leriglitazone in adrenomyeloneuropathy (AMN)

Minoryx presents topline results from…

Minoryx’s clinical candidate leriglitazone shows clinical benefit in a proof of concept Phase 2 study in Friedreich´s ataxia

Minoryx’s clinical candidate leriglitazone shows…

Minoryx’s preclinical data for leriglitazone in Friedreich’s Ataxia published in Neurobiology of Disease Journal

Minoryx’s preclinical data for leriglitazone…

European Investment Bank provides Minoryx with up to €25 million to support development of breakthrough therapies in orphan neurodegenerative diseases

European Investment Bank provides Minoryx…

Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau

Minoryx Therapeutics and Sperogenix Therapeutics…

Minoryx Therapeutics in the news

Minoryx Therapeutics in the news

Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD

Minoryx Therapeutics receives US FDA…

Minoryx Therapeutics receives Orphan Drug Designation from the European Commission for leriglitazone in the treatment of Friedreich’s Ataxia

Minoryx Therapeutics receives Orphan Drug…